JosephAPidalaMDPhD

Hematologic Oncology

Blood and Marrow Transplantation

Overview of Dr. Pidala

Dr. Joseph Pidala is an oncologist in Tampa, FL and is affiliated with H. Lee Moffitt Cancer Center and Research Institute. He received his medical degree from University of South Florida Morsani College of Medicine and has been in practice 13 years. Dr. Pidala accepts several types of health insurance, listed below. He is one of 173 doctors at H. Lee Moffitt Cancer Center and Research Institute who specialize in Oncology. He has more than 100 publications and over 500 citings.

Office
2 Columbia Dr
Tampa, FL 33606
Book by Phone+1(620) 390-2494

Education & Training

University of South Florida MorsaniFellowship, Hematology and Medical Oncology, 2007 - 2010
Beth Israel Deaconess Medical CenterResidency, Internal Medicine, 2004 - 2007
University of South Florida College of MedicineClass of 2004

Certifications & Licensure

FL State Medical License 2010 - 2026
American Board of Internal Medicine Medical Oncology

Clinical Trials

Melphalan+Bortezomib as a Conditioning Regimen for Autologous and Allogeneic Stem Cell Transplants in Multiple Myeloma Start of enrollment: 2009 Jun 18
Completed
Phase 2
Histone Deacetylase Inhibitor LBH589 in Addition to Corticosteroids in Patients With Acute Graft Versus Host Disease (GVHD) Start of enrollment: 2010 Apr 01
Completed
Phase 1, Phase 2
Imatinib and Rituximab in Treating Cutaneous Sclerosis in Patients With Chronic Graft-Versus-Host Disease Start of enrollment: 2011 Mar 01
Completed
Phase 2
Intravenous Administration of RGI-2001 in Patient Undergoing Allogenic Hematopoietic Stem Cell Transplantation (AHSCT) Start of enrollment: 2011 Sep 01
Completed
Phase 1, Phase 2
Ofatumumab as Primary Therapy of Chronic Graft Versus Host Disease Start of enrollment: 2012 Nov 14
Completed
Phase 1, Phase 2
Tacrolimus, Sirolimus and Ustekinumab vs. Tacrolimus and Sirolimus for the Prevention of Acute Graft-Versus-Host Disease Start of enrollment: 2013 Feb 25
Completed
Phase 2
Ex-vivo Expanded Donor Regulatory T Cells for Prevention of Acute Graft-Versus-Host Disease Start of enrollment: 2014 Oct 29
Completed
Phase 1
In Vivo Treg Expansion and Graft-Versus-Host Disease Prophylaxis Start of enrollment: 2014 Mar 25
Completed
Phase 2
Novel Approaches for Graft-versus-Host Disease Prevention Compared to Contemporary Controls (BMT CTN 1203) Start of enrollment: 2014 Aug 01
Completed
Phase 2
Carfilzomib in Treating Patients With Chronic Graft-Versus-Host Disease Start of enrollment: 2015 Nov 12
Completed
Phase 2
Study of Quality of Life in Older vs. Younger Adult Patients Undergoing Allogeneic Hematopoietic Cell Transplantation for Myelodysplastic Syndromes Start of enrollment: 2018 Jul 23
Completed
Acalabrutinib for the Treatment of Chronic Graft Versus Host Disease Start of enrollment: 2020 Dec 12
Recruiting
Phase 2
Predicting the Quality of Response to Specific Treatments in Patients With cGVHD, PQRST Study Start of enrollment: 2020 Jun 29
Recruiting
Roles: Contact, Principal Investigator
MM CAR-T to Upgrade Response BMTCTN1902 Start of enrollment: 2022 Jan 05
Active, not recruiting
Phase 2
Roles: Contact
Close Assessment and Testing for Chronic Graft Versus Host Disease, CATCH Study Start of enrollment: 2019 Sep 13
Recruiting
Roles: Principal Investigator, Contact
Ustekinumab for the Prevention of Acute Graft-versus-Host Disease After Unrelated Donor Hematopoietic Cell Transplant Start of enrollment: 2021 May 14
Recruiting
Phase 2
Roles: Principal Investigator, Contact
Join now to see all

Publications & Presentations

PubMed

Longitudinal tear cytokine biomarkers: an analysis from the Close Assessment and Testing for Chronic Graft-vs.-Host disease (CATCH) protocol: Predictive tear cytokine ...
Najla El Jurdi, Betty K Hamilton, Joseph A Pidala, Lynn Onstad, Christine Mun
Transplantation and Cellular Therapy. 2025-02-07
Comparison of Outcomes of Haploidentical Peripheral Blood Stem Cell Transplantation with Post-Transplant Cyclophosphamide in Older Versus Younger Patients.
Giacomo Adoncecchi, Ambuj Kumar, Krishnakar Mogili, Rawan Faramand, Hien Liu
Cancers. 2025-01-19
Development of the Lee Symptom Scale-Skin Sclerosis for chronic GVHD-associated sclerosis.
Emily Baumrin, Joseph A Pidala, Sandra Mitchell, Lynn Onstad, Stephanie J Lee
Blood. 2025-01-14

Abstracts/Posters

Equate, a Phase 1b/2 Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of a Novel Targeted Anti-CD6 Therapy, Itolizu...
Joseph Pidala, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Clearance of Somatic Gene Mutations in Patients with Acute Myeloid Leukemia Prior to Allogeneic Hematopoietic Cell Transplantation (HCT) Predicts Outcome
Joseph Pidala, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Human CD83 Targeted Chimeric Antigen Receptor T Cell for the Prevention of Graft Versus Host Disease and Treatment of Myeloid Leukemia
Joseph Pidala, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
CD34+ Cell Dose Influences Survival after Allogeneic Peripheral Blood Stem Cell Transplantation with Post-Transplant Cyclophosphamide
Joseph Pidala, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Impact of TBI-Based Conditioning Regimen on Outcomes of Patients with Acute Lymphoblastic Leukemia Undergoing Allogeneic Hematopoietic Cell Transplant: Systematic Revi...
Joseph Pidala, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Early Broad-Spectrum Antibiotics and Risk of Acute Graft-Versus-Host Disease in Children: An Analysis from the Center for International Blood and Marrow Transplantatio...
Joseph Pidala, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Join now to see all

Press Mentions

Phase 1 Trial Demonstrates Encouraging Clinical Benefit and Promising Safety Profile of Pacritinib for the Prevention of Graft-Versus-Host Disease Published in Clinical Cancer ResearchMarch 22nd, 2021
Several Factors May Affect Immune Suppression Discontinuation After HCTSeptember 26th, 2019
Race, Ethnicity Affect Likelihood of Finding a Suitable Unrelated Stem Cell Donor for Cancer PatientsSeptember 11th, 2012
Join now to see all

Insurance Accepted

Aetna Choice POS II
Aetna HMO
AvMed Health Open Access
BCBS Blue Card PPO
BCBS California PPO
BCBS Florida BlueCare HMO
BCBS Florida NetworkBlue
BCBS Florida Preferred Patient Care PPO
Blue Shield California PPO
CIGNA HMO
CIGNA Open Access
CIGNA PPO
Coventry Florida - Employer Group PPO
First Health PPO
Great West PPO
Humana ChoiceCare Network PPO
Multiplan PHCS PPO
Multiplan PPO
Sagamore Health Plus
United Healthcare - Direct Choice Plus POS
United Healthcare - Direct Options PPO
Please verify your coverage with the provider's office directly when scheduling an appointment